What You Should Know:
– Amae Health, a Public Benefit Corporation (PBC) and leader in outpatient treatment for Severe Mental Illness (SMI), announced the close of a $25M of pre-empted Series B financing led by Altos Ventures.
– The funding brings Amae’s total funding to more than $50M and will accelerate the company’s mission to transform how conditions like schizophrenia, bipolar disorder, and treatment-resistant depression are understood and treated.
Achieving Significant and Sustainable Clinical Outcomes
Traditional treatment models have historically struggled to move the needle for the more than 15 million Americans living with SMI. Amae is pioneering a different path by combining compassionate, in-person, team-based care with responsibly deployed AI.
This integrated approach has achieved striking results since the company opened its first clinic in 2022 and partnered with leading systems like NewYork-Presbyterian, Cedars-Sinai, and Stanford Health Care:
- Reduced Readmissions: 30-day hospital readmissions were reduced to less than 4%, significantly lower than the 23% national average.
- Clinical Improvement: The platform achieved measurement-based care score improvements of 76% in mania, 61% in psychosis, and 49% in suicidality.
- Patient Experience: The company achieved a high Net Promoter Score (NPS) of 90, reflecting exceptional patient experience.
“Our north star is a true cure, defined as it is in oncology: five or more years of remission,” said Stas Sokolin, Co-Founder and CEO of Amae Health.
Responsible AI Features Enhance Precision Medicine
Unlike virtual-only models, Amae couples face-to-face care with a precision medicine platform built on Palantir Foundry. This system integrates data from wearables, measurement-based assessments, and patient records, enabling providers to identify patterns and track treatment response.
Three new AI features are reshaping how clinicians care for patients:
- Patient-at-a-Glance: A unified dashboard synthesizes inputs from clinical assessments, wearables, and health records, providing providers with a clear, longitudinal view of patient progress.
- Point of Care Assistant: An AI-powered assistant monitors patient status, flags meaningful changes, and offers treatment recommendations, with providers retaining full control over decisions.
- Symptomology Phenotyping: Uses symptom clustering based on longitudinal patient data to create digital phenotypes, allowing providers to deliver highly effective, precise care tailored to a patient’s unique set of symptoms.
National Expansion
The new funding will accelerate the opening of Amae clinics nationwide, advance the proprietary AI platform, and support research into SMI conditions. Amae has also established the Amae Institute, a center dedicated to partnering with leading research hospitals and academic experts to accelerate the scientific progress needed to achieve long-term remission and a cure.
